At the Financial Times’ Global Pharma and Biotech Summit 2024, a panel discussed ways to prepare for the high number of incoming patent expiries and how to protect key drugs.
Financial Times Live Global Pharma and Biotech Summit
At the Financial Times’ Global Pharma and Biotech Summit 2024, a panel discussed initiatives aimed at bringing cell and gene therapies to low- and middle-income countries.
Advertisement
At the Financial Times’ Global Pharma and Biotech Summit 2024, a breakout panel discussed how dealmaking remains vital for biopharma companies facing pipeline and revenue pressures.
At the Financial Times’ Global Pharma and Biotech Summit 2024, Christophe Weber, president and CEO, Takeda, discusses how trust and collaboration between the biopharma industry and stakeholders can be implemented to support successful healthcare transformation.
Advertisement
Advertisement
Trending on PharmExec
1
Your Phase III Clinical Protocol Is Your Initial Product Launch
2
AstraZeneca Enters $4.7 Billion Collaboration Agreement with CSPC Pharmaceuticals
3
Bringing Huntington’s Story to the Public: Q&A with Heather DeMyers
4
Public Citizen Files Suit Against Trump Administration for Undisclosed Details of Pfizer and Eli Lilly Drug-Pricing Deals: Report
5